The Role of Oncogenes and Redox Signaling in the Regulation of PD-L1 in Cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Role of Oncogenes and Redox Signaling in the Regulation of PD-L1 in Cancer
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 17, Pages 4426
Publisher
MDPI AG
Online
2021-09-02
DOI
10.3390/cancers13174426
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Diverse effects of chemotherapeutic agents on immune cell function and implications in immunochemotherapy
- (2021) Christophe Glorieux et al. Cancer Communications
- Immunotherapy for ALK-Rearranged Non-Small Cell Lung Cancer: Challenges Inform Promising Approaches
- (2021) Kamya Sankar et al. Cancers
- Pharmacological activation of p53 triggers viral mimicry response thereby abolishing tumor immune evasion and promoting anti-tumor immunity
- (2021) Xiaolei Zhou et al. Cancer Discovery
- Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies
- (2021) Kenneth K. W. To et al. Frontiers in Oncology
- Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis
- (2021) Giorgia Guaitoli et al. Translational Lung Cancer Research
- IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma
- (2020) Ting Li et al. CANCER LETTERS
- EGFR‐ERK pathway regulates CSN6 to contribute to PD‐L1 expression in glioblastoma
- (2020) Lingrui Su et al. MOLECULAR CARCINOGENESIS
- Placental Protein 13 (Galectin-13) Polarizes Neutrophils Toward an Immune Regulatory Phenotype
- (2020) Lenka Vokalova et al. Frontiers in Immunology
- Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma
- (2020) Haijing Deng et al. Liver Cancer
- Emerging Roles of ALK in Immunity and Insights for Immunotherapy
- (2020) Lan Wang et al. Cancers
- Spectrum of EGFR aberrations and potential clinical implications: insights from integrative pan‐cancer analysis
- (2020) Haijing Liu et al. Cancer Communications
- Regulation of PD-L1 expression on cancer cells with ROS-modulating drugs
- (2020) Christian Bailly LIFE SCIENCES
- Overexpression of GLT1D1 induces immunosuppression through glycosylation of PD‐L1 and predicts poor prognosis in B‐cell lymphoma
- (2020) Xiaoxia Liu et al. Molecular Oncology
- Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer
- (2020) G. Lamberti et al. ANNALS OF ONCOLOGY
- Akt-targeted therapy as a promising strategy to overcome drug resistance in breast cancer – A comprehensive review from chemotherapy to immunotherapy
- (2020) Parham Jabbarzadeh Kaboli et al. PHARMACOLOGICAL RESEARCH
- Tumor-Associated Neutrophils Dampen Adaptive Immunity and Promote Cutaneous Squamous Cell Carcinoma Development
- (2020) Sokchea Khou et al. Cancers
- The role of genetic polymorphism within PD-L1 gene in cancer. Review
- (2020) Agnieszka Kula et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
- Immune escape: A critical hallmark in solid tumors
- (2020) Keywan Mortezaee LIFE SCIENCES
- Pharmacological inhibition of FGFR modulates the metastatic immune microenvironment and promotes response to immune checkpoint blockade
- (2020) Saeed S Akhand et al. Cancer Immunology Research
- Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker
- (2020) Zhengyi Wang et al. Cancer Medicine
- Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma
- (2020) Hao Sun et al. EBioMedicine
- The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors
- (2020) Matthew H Taylor et al. Future Oncology
- The cross-talk between STAT1/STAT3 and ROS up-regulates PD-L1 and promotes the release of pro-inflammatory/immune suppressive cytokines in primary monocytes infected by HHV-6B
- (2020) Maria Anele Romeo et al. VIRUS RESEARCH
- Regulation of PD-L1 expression in K-ras-driven cancers through ROS-mediated FGFR1 signaling
- (2020) Christophe Glorieux et al. Redox Biology
- Translation control of the immune checkpoint in cancer and its therapeutic targeting
- (2019) Yichen Xu et al. NATURE MEDICINE
- Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1
- (2019) Yu Pan et al. OncoImmunology
- Nuclear localization of PD-L1: artifact or reality?
- (2019) Hara Polioudaki et al. CELLULAR ONCOLOGY
- Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1
- (2019) Cecilia Roux et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- HDAC3 inhibition up-regulates PD-L1 expression in B-cell lymphomas and augments the efficacy of anti-PD-L1 therapy
- (2019) Siyu Deng et al. MOLECULAR CANCER THERAPEUTICS
- YY1 regulates cancer cell immune resistance by modulating PD-L1 expression
- (2019) Emily Hays et al. DRUG RESISTANCE UPDATES
- FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway
- (2019) Piao Li et al. JOURNAL OF IMMUNOLOGY
- MAPK pathway activity plays a key role in PD‐L1 expression of lung adenocarcinoma cells
- (2019) Thijs S Stutvoet et al. JOURNAL OF PATHOLOGY
- Loss of the transcriptional repressor TGIF1 results in enhanced Kras-driven development of pancreatic cancer
- (2019) Ching-Chieh Weng et al. Molecular Cancer
- The next‐generation BET inhibitor, PLX51107, delays melanoma growth in a CD8‐mediated manner
- (2019) Dan A. Erkes et al. Pigment Cell & Melanoma Research
- Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy
- (2019) Abdullah Al Emran et al. TRENDS IN IMMUNOLOGY
- Aberrant PD-1 ligand expression contributes to the myocardial inflammatory injury caused by Coxsackievirus B infection
- (2019) Tianying Wang et al. ANTIVIRAL RESEARCH
- EZH2 regulates PD-L1 expression via HIF-1α in non-small cell lung cancer cells
- (2019) Yuetao Zhao et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- HDAC6 inhibition synergizes with anti-PD-L1 therapy in ARID1A-inactivated ovarian cancer.
- (2019) Takeshi Fukumoto et al. CANCER RESEARCH
- Adjuvant Chemotherapy Increases Programmed Death-Ligand 1 (PD-L1) Expression in Non–small Cell Lung Cancer Recurrence
- (2019) Max Lacour et al. Clinical Lung Cancer
- Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer
- (2019) Li Wang et al. EUROPEAN UROLOGY
- Immunomodulatory MicroRNAs in cancer: targeting immune checkpoints and the tumor microenvironment
- (2019) Hany A. Omar et al. FEBS Journal
- Co‐inhibition of BET proteins and PD‐L1 as a potential therapy for OSCC through synergistic inhibition of FOXM1 and PD‐L1 expressions
- (2019) Wei Wang et al. JOURNAL OF ORAL PATHOLOGY & MEDICINE
- Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer
- (2019) Sandra Assoun et al. LUNG CANCER
- The combined effect of FGFR inhibition and PD-1 blockade promotes tumor-intrinsic induction of antitumor immunity
- (2019) Sangeetha Palakurthi et al. Cancer Immunology Research
- PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer
- (2019) Trine Vilsbøll Larsen et al. Cancer Communications
- Checkpoint inhibitors in pancreatic cancer
- (2019) Andreas Henriksen et al. CANCER TREATMENT REVIEWS
- IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression
- (2019) Alexander Thiem et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- ARF6 and AMAP1 are major targets of KRAS and TP53 mutations to promote invasion, PD-L1 dynamics, and immune evasion of pancreatic cancer
- (2019) Shigeru Hashimoto et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PD-L1 regulation by SDH5 via β-catenin/ZEB1 signaling
- (2019) Zhan Tuo et al. OncoImmunology
- PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition
- (2019) Cretella et al. Cancers
- Clinical Significance of PD-L1 Expression in Both Cancer and Stroma Cells of Cholangiocarcinoma Patients
- (2019) Yuki Kitano et al. ANNALS OF SURGICAL ONCOLOGY
- Doxorubicin inhibits PD-L1 expression by enhancing TTP-mediated decay of PD-L1 mRNA in cancer cells
- (2019) Dong Jun Kim et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy
- (2019) Huiying Han et al. CANCER CELL
- Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer
- (2019) Koji Teramoto et al. LUNG CANCER
- Glutamine Deprivation Induces PD-L1 Expression via Activation of EGFR/ERK/c-Jun Signaling in Renal Cancer
- (2019) Guofeng Ma et al. MOLECULAR CANCER RESEARCH
- Mechanisms Controlling PD-L1 Expression in Cancer
- (2019) Jong-Ho Cha et al. MOLECULAR CELL
- Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
- (2019) Wendy Mao et al. Journal for ImmunoTherapy of Cancer
- EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma
- (2019) Gang Xiao et al. Journal for ImmunoTherapy of Cancer
- A Tumor-Specific Super-Enhancer Drives Immune Evasion by Guiding Synchronous Expression of PD-L1 and PD-L2
- (2019) Yuanpei Xu et al. Cell Reports
- Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1
- (2018) Chia-Wei Li et al. CANCER CELL
- EGFR activation induced Snail-dependent EMT and myc-dependent PD-L1 in human salivary adenoid cystic carcinoma cells
- (2018) Yang Wang et al. CELL CYCLE
- E3 ubiquitin ligases Cbl-b and c-Cbl downregulate PD-L1 in EGFR wild-type non-small cell lung cancer
- (2018) Shuo Wang et al. FEBS LETTERS
- Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer
- (2018) Amir Mehrvarz Sarshekeh et al. Future Oncology
- GenomicERBB2/ERBB3mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis
- (2018) Maolan Li et al. GUT
- Efficacy of programmed death 1 (PD-1) and programmed death 1 ligand (PD-L1) inhibitors in patients with FGFR mutations and gene fusions: Results from a data analysis of an ongoing phase 2 study of erdafitinib (JNJ-42756493) in patients (pts) with advanced urothelial cancer (UC).
- (2018) Arlene O. Siefker-Radtke et al. JOURNAL OF CLINICAL ONCOLOGY
- IFNAR1 Controls Autocrine Type I IFN Regulation of PD-L1 Expression in Myeloid-Derived Suppressor Cells
- (2018) Wei Xiao et al. JOURNAL OF IMMUNOLOGY
- MYC inhibition increases PD-L1 expression induced by IFN-γ in hepatocellular carcinoma cells
- (2018) Jiahuan Zou et al. MOLECULAR IMMUNOLOGY
- Epigenetic regulators of programmed death-ligand 1 expression in human cancers
- (2018) Sachin Kumar et al. Translational Research
- BET bromodomain inhibitor JQ1 preferentially suppresses EBV-positive nasopharyngeal carcinoma cells partially through repressing c-Myc
- (2018) Ning Li et al. Cell Death & Disease
- Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion
- (2018) Yiting Wang et al. Frontiers in Pharmacology
- Epigenetic treatment of multiple myeloma mediates tumor intrinsic and extrinsic immunomodulatory effects
- (2018) Lien De Beck et al. OncoImmunology
- Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types
- (2018) Kristin C. Hicks et al. OncoImmunology
- Stromal PD-1 / PD-L1 expression predicts outcome in colon cancer patients
- (2018) Jacqueline Wyss et al. Clinical Colorectal Cancer
- Histone deacetylase 6 in cancer
- (2018) Ting Li et al. Journal of Hematology & Oncology
- EBV up-regulates PD-L1 on the surface of primary monocytes by increasing ROS and activating TLR signaling and STAT3
- (2018) Maria Saveria Gilardini Montani et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Epidermal growth factor induces STAT1 expression to exacerbate the IFNr-mediated PD-L1 axis in epidermal growth factor receptor-positive cancers
- (2018) Chun-Chia Cheng et al. MOLECULAR CARCINOGENESIS
- ERADicate Tumor Progression with Metformin
- (2018) Lena-Sophie Dreher et al. MOLECULAR CELL
- Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1
- (2018) Jong-Ho Cha et al. MOLECULAR CELL
- Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade
- (2018) Ye Qin et al. ONCOGENE
- Chemotherapeutic Treatments Increase PD-L1 Expression in Esophageal Squamous Cell Carcinoma through EGFR/ERK Activation
- (2018) Hoi Yan Ng et al. Translational Oncology
- Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment
- (2018) Hongge Liang et al. OncoTargets and Therapy
- Gastric cancer mesenchymal stem cells derived IL-8 induces PD-L1 expression in gastric cancer cells via STAT3/mTOR-c-Myc signal axis
- (2018) Li Sun et al. Cell Death & Disease
- Interplay between interferon regulatory factor 1 and BRD4 in the regulation of PD-L1 in pancreatic stellate cells
- (2018) Kazumi Ebine et al. Scientific Reports
- DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer
- (2018) Varun Sasidharan Nair et al. Clinical Epigenetics
- Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gαq and Gα11 and kill uveal melanoma cells
- (2018) Laurence Booth et al. CANCER BIOLOGY & THERAPY
- A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
- (2018) Livnat Jerby-Arnon et al. CELL
- ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity
- (2018) Tim H. Holmström et al. MOLECULAR CANCER THERAPEUTICS
- Fibroblast growth factor receptors as treatment targets in clinical oncology
- (2018) Masaru Katoh Nature Reviews Clinical Oncology
- EBV-positive diffuse large B-cell lymphoma features PD-L1 protein but not mRNA overexpression
- (2018) Tian Xue et al. PATHOLOGY
- PD-L1 methylation regulates PD-L1 expression and is associated with melanoma survival
- (2018) Goran Micevic et al. Pigment Cell & Melanoma Research
- Specific zinc finger‐induced methylation of PD ‐L1 promoter inhibits its expression
- (2018) Xue Li et al. FEBS Open Bio
- DNA methylation of immune checkpoints in the peripheral blood of breast and colorectal cancer patients
- (2018) Asma A. Elashi et al. OncoImmunology
- The antimetastatic effect and underlying mechanisms of thioredoxin reductase inhibitor ethaselen
- (2018) Xiaoqing Zheng et al. FREE RADICAL BIOLOGY AND MEDICINE
- Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
- (2017) Matthew A. Coelho et al. IMMUNITY
- Posttranscriptional Control of PD-L1 Expression by 17β-Estradiol via PI3K/Akt Signaling Pathway in ERα-Positive Cancer Cell Lines
- (2017) Lingyun Yang et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma
- (2017) V Atsaves et al. LEUKEMIA
- MYC expression correlates with PD-L1 expression in non-small cell lung cancer
- (2017) Eun Young Kim et al. LUNG CANCER
- Development and validation of a novel clinical fluorescence in situ hybridization assay to detect JAK2 and PD-L1 amplification: a fluorescence in situ hybridization assay for JAK2 and PD-L1 amplification
- (2017) Meixuan Chen et al. MODERN PATHOLOGY
- Chemotherapy induces tumor immune evasion by upregulation of programmed cell death ligand 1 expression in bone marrow stromal cells
- (2017) Mengqi Yang et al. Molecular Oncology
- Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
- (2017) Riccardo Mezzadra et al. NATURE
- Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
- (2017) Jinfang Zhang et al. NATURE
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- (2017) David P. Carbone et al. NEW ENGLAND JOURNAL OF MEDICINE
- BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer
- (2017) J Wang et al. ONCOGENE
- Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2
- (2017) Krzysztof M. Zak et al. STRUCTURE
- Induction of PD-L1 expression by epidermal growth factor receptor–mediated signaling in esophageal squamous cell carcinoma
- (2017) Wencheng Zhang et al. OncoTargets and Therapy
- Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice
- (2017) Janet Lau et al. Nature Communications
- EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release
- (2017) Koung Jin Suh et al. Oncotarget
- PD-L1 confers resistance to EGFR mutation-independent tyrosine kinase inhibitors in non-small cell lung cancer via upregulation of YAP1 expression
- (2017) Jai-Nien Tung et al. Oncotarget
- Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer
- (2016) Julie George et al. CLINICAL CANCER RESEARCH
- The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer
- (2016) Nan Zhang et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
- (2016) Margaretha G.M. Roemer et al. JOURNAL OF CLINICAL ONCOLOGY
- MYC regulates the antitumor immune response through CD47 and PD-L1
- (2016) S. C. Casey et al. SCIENCE
- PD-L1 expression in human cancers and its association with clinical outcomes
- (2016) Jinming Yu et al. OncoTargets and Therapy
- Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
- (2016) Chia-Wei Li et al. Nature Communications
- A strong host response and lack of MYC expression are characteristic for diffuse large B cell lymphoma transformed from nodular lymphocyte predominant Hodgkin lymphoma
- (2016) Bianca Schuhmacher et al. Oncotarget
- PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy
- (2016) Heidrun Gevensleben et al. Oncotarget
- Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants
- (2016) Subrata Chowdhury et al. Oncotarget
- AKT-STAT3 Pathway as a Downstream Target of EGFR Signaling to Regulate PD-L1 Expression on NSCLC cells
- (2016) Sherif Abdelhamed et al. Journal of Cancer
- Regulation of cytotoxic T-cell responses by p53 in cancer
- (2016) Mitchell W. Braun et al. Translational Cancer Research
- RAS–Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers
- (2016) Hidetoshi Sumimoto et al. PLoS One
- Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients
- (2016) Arun Satelli et al. Scientific Reports
- EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB
- (2015) Kailong Lin et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFN That Induce PD-L1 Expression in Head and Neck Cancer
- (2015) F. Concha-Benavente et al. CANCER RESEARCH
- Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer
- (2015) Kristin J. Lastwika et al. CANCER RESEARCH
- TP53: an oncogene in disguise
- (2015) T Soussi et al. CELL DEATH AND DIFFERENTIATION
- Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer
- (2015) K. Ota et al. CLINICAL CANCER RESEARCH
- PDL1 Regulation by p53 via miR-34
- (2015) Maria Angelica Cortez et al. JNCI-Journal of the National Cancer Institute
- Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
- (2015) Nan Chen et al. Journal of Thoracic Oncology
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Response Regulation in the Tumor Microenvironment by Hypoxia
- (2015) Sara Labiano et al. SEMINARS IN ONCOLOGY
- Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer
- (2015) Michael T. Barrett et al. Oncotarget
- PDL1 Regulation by p53 via miR-34
- (2015) Maria Angelica Cortez et al. JNCI-Journal of the National Cancer Institute
- EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1α and STAT3
- (2015) Jaemoon Koh et al. OncoImmunology
- Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression
- (2015) Roberto Bellucci et al. OncoImmunology
- Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients
- (2015) Shaodong Hong et al. OncoImmunology
- EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy
- (2015) Wenfeng Fang et al. Oncotarget
- PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
- (2014) A D'Incecco et al. BRITISH JOURNAL OF CANCER
- Loss of Lkb1 and Pten Leads to Lung Squamous Cell Carcinoma with Elevated PD-L1 Expression
- (2014) Chunxiao Xu et al. CANCER CELL
- STAT1 Drives Tumor Progression in Serous Papillary Endometrial Cancer
- (2014) B. Kharma et al. CANCER RESEARCH
- Dendritic cells with an increased PD-L1 by TGF-β induce T cell anergy for the cytotoxicity of hepatocellular carcinoma cells
- (2014) Shasha Song et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation
- (2014) Muhammad Zaeem Noman et al. JOURNAL OF EXPERIMENTAL MEDICINE
- MicroRNA-513 Regulates B7-H1 Translation and Is Involved in IFN- -Induced B7-H1 Expression in Cholangiocytes
- (2014) A.-Y. Gong et al. JOURNAL OF IMMUNOLOGY
- Immune Suppression by Neutrophils in HIV-1 Infection: Role of PD-L1/PD-1 Pathway
- (2014) Nathan L. Bowers et al. PLoS Pathogens
- Histone H2AX suppresses translocations in lymphomas ofEμ-c-Myctransgenic mice that contain a germline amplicon of tumor-promoting genes
- (2013) Angela Fusello et al. CELL CYCLE
- Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy
- (2013) Omid Hamid et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
- (2013) E. A. Akbay et al. Cancer Discovery
- Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy
- (2012) M. R. Green et al. CLINICAL CANCER RESEARCH
- The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
- (2012) X. Jiang et al. CLINICAL CANCER RESEARCH
- B7-H1, Which Represses EBV-Immortalized B Cell Killing by Autologous T and NK Cells, Is Oppositely Regulated by c-Myc and EBV Latency III Program at Both mRNA and Secretory Lysosome Levels
- (2012) S. Durand-Panteix et al. JOURNAL OF IMMUNOLOGY
- Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma
- (2012) H Tamura et al. LEUKEMIA
- Immunotherapy for melanoma
- (2011) Jeffrey Weber CURRENT OPINION IN ONCOLOGY
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
- (2010) M. R. Green et al. BLOOD
- Interferon- and tumor necrosis factor- induce an immunoinhibitory molecule, B7-H1, via nuclear factor- B activation in blasts in myelodysplastic syndromes
- (2010) A. Kondo et al. BLOOD
- PD-L1 expression on tolerogenic APCs is controlled by STAT-3
- (2010) Sabine J. Wölfle et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- PD-1 Ligand Expression by Human Colonic Myofibroblasts/Fibroblasts Regulates CD4+ T-Cell Activity
- (2008) Irina V. Pinchuk et al. GASTROENTEROLOGY
- The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors
- (2008) D. Y.-w. Lin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
- (2008) M. Marzec et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search